RNA

Avidity Biosciences, Inc. [RNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RNA Stock Summary

In the News

RNA Financial details

Company Rating
-
Market Cap
1.92B
Income
-207.02M
Revenue
9.56M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
253
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.37
Forward P/E
-
PEG
3.45
P/S
83.78
P/B
1.64
P/C
-
P/FCF
-4.74
Quick Ratio
11.14
Current Ratio
11.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.83
EPS next Y
-
EPS next Q
-
EPS this Y
-10.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
27.61%
Revenue last 5Y
32.75%
Revenue Q/Q
-22.18%
EPS Q/Q
11.27%
-
-
-
-
SMA20
-
SMA50
58.62%
SMA100
64.29%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
-35%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-2144%
Profit Margin
-1917%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.825-27.66
52W High
+48.37%
52W Low
+901.5%
RSI
42
Rel Volume
3.83
Avg Volume
1.19M
Volume
4.56M
Perf Week
-20.45%
Perf Month
7.28%
Perf Quarter
24.8%
Perf Half Y
28.77%
-
-
-
-
Beta
0.772
-
-
Volatility
2.74%, 2.5%
Prev Close
-10.46%
Price
40.06
Change
-6.97%

Something similar

Top by Market Cap
1YD.DE
NVDA
GOOG
BRYN.DE
ABEA.DE
Same Sector
BBLGW
IMMX
0R2S.L
MGTA
PEL.NS
Same Price Range
TXG.TO
GUSA
JISLJALEQS.NS
HJPNX
FCPIX
Similar Market Cap
PLAB
JBEM.DE
RUG.ST
NSS
THYCF

Company Profile

Healthcare Biotechnology
  • Volume Average 1.19M
  • Market Capitalization 1.92B
  • Employee 253
  • CEO Ms. Sarah Boyce
  • Headquarters San Diego,CA,US
  • IPO Date 2020-06-12
  • Website https://www.aviditybiosciences.com

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.